These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16679946)

  • 41. High-dose deferoxamine treatment (intravenous) for thalassaemia patients with cardiac complications.
    Ghader FR; Kousarian M; Farzin D
    East Mediterr Health J; 2007; 13(5):1053-9. PubMed ID: 18290397
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment.
    Levine JE; Cohen A; MacQueen M; Martin M; Giardina PJ
    J Pediatr Hematol Oncol; 1997; 19(2):139-41. PubMed ID: 9149744
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Decorporation of Iron Metal Using Dialdehyde Cellulose-Deferoxamine Microcarrier.
    Tyagi P; Kumar A; Gupta D; Singh H
    AAPS PharmSciTech; 2017 Jan; 18(1):156-165. PubMed ID: 26912356
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Post-transfusion hemochromatosis. Results of a study carried out in Blood Transfusion Centers. Analysis of 15 cases treated with subcutaneous perfusion of Desferal. Working group "Transfusion Techniques and Therapeutics"].
    Jaulmes D; Quarre MC; Audat F; Gaonach MJ
    Transfus Clin Biol; 1994; 1(1):55-64. PubMed ID: 8186855
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Continuous intravenous deferoxamine infusion. Treatment of secondary hemochromatosis in adults.
    Blume KG; Beutler E; Chillar RK; Fahey JL; Sharkoff D; Zia PK
    JAMA; 1978 May; 239(20):2149-51. PubMed ID: 642157
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of high doses of deferoxamine (Desferal) in an adult patient with acute iron overdosage.
    Peck MG; Rogers JF; Rivenbark JF
    J Toxicol Clin Toxicol; 1982 Oct; 19(8):865-9. PubMed ID: 7182516
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Deferoxamine: potential novel topical therapeutic for chronic wounds.
    Tchanque-Fossuo CN; Dahle SE; Buchman SR; Isseroff RR
    Br J Dermatol; 2017 Apr; 176(4):1056-1059. PubMed ID: 28418133
    [No Abstract]   [Full Text] [Related]  

  • 48. A massive intraventricular thrombosis by disseminated mucormycosis in a patient with myelodysplastic syndrome during deferoxamine therapy.
    Kubota N; Miyazawa K; Shoji N; Sumi M; Nakajima A; Kimura Y; Oshiro H; Ebihara Y; Ohyashiki K
    Haematologica; 2003 Nov; 88(11):EIM13. PubMed ID: 14607766
    [No Abstract]   [Full Text] [Related]  

  • 49. Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.
    Gallant T; Boyden MH; Gallant LA; Carley H; Freedman MH
    Am J Med; 1987 Dec; 83(6):1085-90. PubMed ID: 3503576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ocular toxicity of high-dose intravenous desferrioxamine.
    Davies SC; Marcus RE; Hungerford JL; Miller MH; Arden GB; Huehns ER
    Lancet; 1983 Jul; 2(8343):181-4. PubMed ID: 6135026
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions.
    Freedman MH; Grisaru D; Olivieri N; MacLusky I; Thorner PS
    Am J Dis Child; 1990 May; 144(5):565-9. PubMed ID: 2330923
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Survival after a severe iron poisoning treated with intermittent infusions of deferoxamine.
    Cheney K; Gumbiner C; Benson B; Tenenbein M
    J Toxicol Clin Toxicol; 1995; 33(1):61-6. PubMed ID: 7837315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Impact of Deferoxamine on Vascularity and Soft-Tissue Biomechanics in a Rat TRAM Flap Model.
    Mericli AF; Das A; Rodeheaver P; Rodeheaver GT; Lin KY
    Plast Reconstr Surg; 2015 Jul; 136(1):125e-127e. PubMed ID: 25803154
    [No Abstract]   [Full Text] [Related]  

  • 54. Red cell ghost-entrapped deferoxamine as a model clinical targeted delivery system for iron chelators and other compounds.
    Green R
    Bibl Haematol; 1985; (51):25-35. PubMed ID: 4004761
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of Neutropenic Murine Models of Iron Overload and Depletion To Study the Efficacy of Siderophore-Antibiotic Conjugates.
    Kidd JM; Abdelraouf K; Nicolau DP
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapid recovery with oral zinc sulphate in deferoxamine-induced presumed optic neuropathy and hearing loss.
    Pinna A; Corda L; Carta F
    J Neuroophthalmol; 2001 Mar; 21(1):32-3. PubMed ID: 11315979
    [No Abstract]   [Full Text] [Related]  

  • 57. Deferoxamine (desferrioxamine). New toxicities for an old drug.
    Bentur Y; McGuigan M; Koren G
    Drug Saf; 1991; 6(1):37-46. PubMed ID: 2029352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deferoxamine in the treatment of acute iron poisoning. Clinical experiences with 172 children.
    Westlin WF
    Clin Pediatr (Phila); 1966 Sep; 5(9):531-5. PubMed ID: 5911317
    [No Abstract]   [Full Text] [Related]  

  • 59. Deferoxamine-related fatal nasal-orbital-cerebral mucormycosis.
    Wu VC; Wang R; Lai TS; Wu KD
    Kidney Int; 2006 Dec; 70(11):1888. PubMed ID: 17130818
    [No Abstract]   [Full Text] [Related]  

  • 60. EVALUATION OF DEFEROXAMINE IN IRON OVERLOAD.
    HWANG YF; BROWN EB
    Arch Intern Med; 1964 Dec; 114():741-53. PubMed ID: 14211586
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.